Molecular precision chemotherapy: Overcoming resistance to targeted therapies?

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1064-1066

  Burdach, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIRTECAN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITHRAMYCIN; PROTEIN TYROSINE KINASE INHIBITOR; TRABECTEDIN; WERNER SYNDROME PROTEIN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; EWING SARCOMA; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; ONCOGENE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DIOXOLES; DNA DAMAGE; FEMALE; HUMANS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; TETRAHYDROISOQUINOLINES;

EID: 84895786398     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3194     Document Type: Article

References (12)

1. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014;20:1190-1203.
2. Available from: http://omim.org/entry/604611.
3. Grohar PJ, WoldemichaelGM, Griffin LB, Mendoza A, Chen QR, Yeung C, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 2011;103:962-78.
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:7391.
5. Grunewald TG, Greulich N, Kontny U, Frühwald M, Rutkowski S, Kordes U, et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 2012;224:124-31.
6. Hummel TR, Chow LM, Fouladi M, Franz D. Pharmacotherapeutic management of pediatric gliomas: current and upcoming strategies. Paediatr Drugs 2013;15:29-42.
7. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
8. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013;14:703-18.
9. Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther 2013;137: 216-24.
10. Solit DB, Jänne PA. Translational medicine: primed for resistance. Nature 2012;483:44-5.
11. Shannon K. Rett Nearburg Symposium 2013 Nov 6-9; San Diego, CA.
12. Burdach S, Jürgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors. Crit Rev Oncol Hematol 2002;41:169-89.